Lexeo Therapeutics, Inc. (LXEO)

NASDAQ: LXEO · USD

$3.12

+0.25 (+8.7%)· Recorded snapshot

Market cap	256M
Net income (ttm)	-87.3M
EPS (ttm)	-$1.15
Shares out	82M
Volume	993,699
Beta	1.64

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -87.3M
EPS (ttm): -$1.15
Market cap: 256M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-46.8

P25 n/aP50 n/aP75 n/a

ROIC-30.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All LXEO indicators

Market & fundamental data

Available fields

175

Groups with data

Currency

USD

Showing 175 of 175 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001907108
Company name	Lexeo Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	52886X107
Earnings date	2026-11-09
Earnings time	bmo
Employees	63
Employees change	2
Employees growth	3.28%
Enterprise value	$51.1M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2017
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2023-11-03
Is primary listing	Yes
Is SPAC	No
ISIN number	US52886X1072
Last 10-K release date	2026-03-30
Last earnings date	2026-08-12
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$256M
Market cap category	Micro-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$3.12
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	LXEO
U.S. state	New York
Website	https://www.lexeotx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-36.72%
FCF / EV yield	-223%
FCF yield	-36.25%
P/B ratio	0.96x
Price / tangible book value	1.04x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.4M
ROA	-27.59%
ROA (5Y)	-37.1%
ROCE	-39.76%
ROE	-46.76%
ROE (5Y)	-67.2%
ROIC	-30.56%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	5
EPS growth years	3
Net income growth quarters	4
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-331,000
Depreciation and amortization	$613,000
EBIT	$-95.1M
EBITDA	$-94.5M
EPS	$-1.15
FCF per share	$-1.08
Financing cash flow	$170.7M
Free cash flow	$-88.7M
Free cash flow minus SBC	$-102.5M
Gross profit	$-66.6M
Investing cash flow	$-25M
Net borrowing	$-515,000
Net cash flow	$57.4M
Net income	$-87.3M
Operating cash flow minus SBC	$-102.2M
Operating income	$-95.1M
Stock-based compensation	$13.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$2.99
Debt / equity	0.03
Interest coverage	-1,302.97
Long-term assets	$37M
Long-term liabilities	$4.1M
Net cash (debt)	$204.9M
Net cash / market cap	83.74%
Net cash growth	65.26%
Net debt / equity	-0.87
Piotroski F-Score	1
Property, plant and equipment	$7.9M
Shareholders' equity	$235.1M
Tangible book value	$235.1M
Tangible book value per share	$2.99
Total assets	$254.9M
Total cash	$211.7M
Total debt	$6.8M
Total liabilities	$19.8M
WACC	12.93%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$217.9M
Current liabilities	$15.7M
Current ratio	13.89
Net working capital	$-6.8M
Quick ratio	13.57
Working capital	$202.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-113.19%
Dividend yield	0%
Shareholder yield	-113.19%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$4.72
1D price change	8.71%
1M price change	-6.95%
1M total return	-6.95%
1W price change	1.99%
1W total return	1.99%
1Y price change	-68.7%
1Y return CAGR	-68.72%
1Y total return	-68.7%
20-day SMA	$3.03
200-day SMA	$5.26
3M price change	-31.1%
3M total return	-31.1%
50-day SMA	$3.84
50-day SMA vs 200-day SMA	50under200
52-week high	$10.99
52-week high date	2025-12-23
52-week low	$2.55
52-week low date	2026-10-19
6M price change	-45.24%
6M total return	-45.24%
All-time high	$22.33
All-time high date	2024-01-18
All-time low	$1.45
All-time low date	2025-04-07
Average true range (ATR)	$0.25
Average volume	1.6M
Beta (1Y)	2.79
Beta (2Y)	2.37
Beta (5Y)	1.64
Change from 52-week high	-71.61%
Change from 52-week low	22.35%
Change from all-time high	-86.21%
Change from all-time low	112.41%
Change from open	10.25%
Day's gap	-1.39%
Dollar volume	$3.1M
High price	$3.13
Low price	$2.81
Monthly RSI	36.44
Open price	$2.83
Position in 52-week range	96.92%
Premarket change	2.44%
Premarket close	$2.87
Premarket price	$2.94
Premarket volume	508
Previous close	$2.87
Price vs 150-day SMA	-34.72%
Price vs 20-day SMA	1.75%
Price vs 200-day SMA	-41.4%
Price vs 50-day SMA	-19.69%
Relative volume	0.62
Return from IPO open	-68.61%
Return from IPO price	-72.89%
RSI	46.26
Sharpe ratio	-1.33
Sortino ratio	-1.7
Volume	993.7K
Weekly RSI	34.51
YTD price change	-68.98%
YTD total return	-68.98%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	51.2M
Float percentage	62.42%
Shares change (QoQ)	5.47%
Shares change (YoY)	113.19%
Shares held by insiders	0.39%
Shares held by institutions	78.69%
Shares outstanding	82M
Short % of float	37.58%
Short % of shares	23.46%
Short ratio	13.9 days

Deeper analysis on LXEO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this LXEO report

Is a complete LXEO research report available?

No complete published report is available for Lexeo Therapeutics, Inc. (LXEO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Lexeo Therapeutics, Inc. (LXEO)

Price

Financial snapshot

Fair-value bridge

Latest news · LXEO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All LXEO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on LXEO

Frequently asked questions